Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun;34(6):337-41.
doi: 10.1093/jjco/hyh064.

A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer

Affiliations

A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer

Wen-Chyi Sheen et al. Jpn J Clin Oncol. 2004 Jun.

Abstract

Background: We conducted this retrospective study to analyze a modified dose schedule of mitoxantrone and prednisolone (MP) in patients with androgen-independent prostate cancer.

Methods: From June 1997 to April 2002, 28 patients were enrolled. Their median age was 69 years (range, 58-79 years). The median duration of hormonal therapy was 30 months (range, 6-84 months). The median performance status was 2. Sixteen of the patients had bone disease only. The chemotherapy consisted of 8 mg/m2 mitoxantrone by intravenous infusion every 3 weeks and 10 mg prednisolone orally twice per day. WHO response criteria, prostatic-specific antigen (PSA), pain and performance status were used to assess the response.

Results: The median number of treatment cycles was six (range, 2-20). Nine (32.1%) and 15 patients (53.8%) had > or =80% and > or =50% reduction in serum PSA level, respectively. Of 16 patients using narcotics, five (31.3%) had a > or =50% reduction in narcotics consumption compared with the baseline. Nine patients (32.1%) showed improved performance. For 12 patients with measurable disease, only two (16.7%) showed a partial response. Grade 3-4 toxicities included neutropenia (three patients), anemia (three patients) and vomiting (one patient). The median survival was 12 months and the median time to PSA progression was 4 months.

Conclusions: This modified regimen is feasible for palliative intent. The toxicity of this regimen is manageable. Exploring further combinations of this regimen with novel agents against androgen-independent prostate cancer is warranted.

PubMed Disclaimer

Publication types